Categories AlphaGraphs, Earnings, Health Care

Johnson & Johnson (JNJ) Q3 earnings, sales beat Street view; stock gains

Earnings of healthcare conglomerate Johnson & Johnson (NYSE: JNJ) increased and topped the Street view in the third quarter helped by a 2% growth in sales. Encouraged by the positive outcome, the management revised up its full-year earnings and sales outlook. The company’s stock gained early Tuesday following the announcement.

Johnson & Johnson (JNJ) Q3 earnings rise 3% on higher revenues

Adjusted earnings rose 3.4% annually to $2.12 per share in the third quarter from $2.05 per share last year and topped the estimates. Reported profit increased to $4.83 billion or $1.81 per share in the three-month period from $3.93 billion or $1.44 per share in the prior-year quarter.

Top-line Beats

Net sales, meanwhile, moved up to $20.73 billion from $20.35 billion in the third quarter of 2018. Market watchers were looking for a lower top-line number. Sales grew 1.2% in the US and advanced 2.6% in the international market. Segment-wise, Consumer and Pharmaceutical sales grew 1.6% and 5.1% respectively, while Medical Devices sales dropped 3.1%.

Related: Johnson & Johnson tumbles on rating downgrade

“Our third-quarter results represent strong performance, driven by competitive underlying growth in Pharmaceuticals and Medical Devices, as well as continued optimization in our Consumer business,” said CEO Alex Gorsky.

Outlook

The company revised up its full-year 2019 sales outlook to the range of $81.8 billion to $82.3 billion from the previous forecast of $80.8-$81.6 billion, representing a 0.2-0.7% annual increase. The guidance for adjusted earnings has been raised to the range of $8.62 per share to $8.67 per share from $8.53-$8.63 per share, which represents a 5.4-6.0% growth.

To drive growth during the remainder of the year, the management bets on its broad-based business model, supported by disciplined portfolio management and focus on transformational innovation.

Also see: Johnson & Johnson Q2 2019 Earnings Call Transcript

After making a positive start to the year, Johnson & Johnson’s shares pared the initial gains in recent weeks and slipped below the $130-mark. The stock, which lost about 6% in the past twelve months, gained modestly during Tuesday’s pre-market trading session.

Also Read:  Pfizer Inc. (PFE) Q2 2020 Earnings Call Transcript

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

Yelp Q2 earnings: All key figures

Yelp (NYSE: YELP) reported second-quarter financial results after the regular trading hours on Thursday. The results were better than what the street had anticipated. YELP shares rose 4% immediately following the

Infographic: Uber (UBER) Q2 loss narrows; revenue beats

Uber Technologies (NYSE: UBER) reported its second-quarter 2020 financial results after the regular trading hours on Thursday. Revenues exceeded the estimates, while the bottom-line missed. Shares of the ride-hailing company

TMobile (TMUS) Q2 revenue up 61%; results beat Street view

TMobile US Inc.  (NASDAQ: TMUS) on Thursday announced financial results for the second quarter of 2020, reporting a 61% increase in revenues aided by strong customer growth. The results also

Top